SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 316 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,993 | +1.6% | 55 | 0.0% | 0.00% | – |
| Q4 2022 | $1,962 | – | 55 | – | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q3 2020 | $5,000 | +400.0% | 224 | +833.3% | 0.00% | – |
| Q4 2019 | $1,000 | -95.7% | 24 | -96.6% | 0.00% | -100.0% |
| Q3 2019 | $23,000 | 0.0% | 704 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $23,000 | +666.7% | 704 | +780.0% | 0.00% | – |
| Q1 2019 | $3,000 | 0.0% | 80 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -25.0% | 80 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | -42.9% | 80 | -34.4% | 0.00% | -100.0% |
| Q2 2018 | $7,000 | 0.0% | 122 | -15.3% | 0.00% | 0.0% |
| Q1 2018 | $7,000 | +40.0% | 144 | +21.0% | 0.00% | – |
| Q4 2017 | $5,000 | 0.0% | 119 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $5,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $5,000 | +400.0% | 119 | +197.5% | 0.00% | – |
| Q1 2017 | $1,000 | – | 40 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |